Retatrutide: Triple Receptor Agonist in Clinical Research

Retatrutide is a synthetic peptide being investigated as a triple agonist: it simultaneously targets three receptors involved in metabolism and energy regulation — the GLP-1, GIP and glucagon receptor.

Mechanism of action in research

The simultaneous activation of three receptor pathways is why retatrutide receives particular attention in metabolic research:

• GLP-1 receptor: Involved in insulin secretion and appetite regulation
• GIP receptor: Plays a role in fat storage and bone metabolism
• Glucagon receptor: Influences hepatic glucose production and energy expenditure

Clinical research phase

At the time of publication, retatrutide was in phase 3 clinical research, being developed by Eli Lilly. As a research compound it is available for use in controlled laboratory environments.

Important: Retatrutide is not approved as a medicine. Nova Labs sells retatrutide exclusively as a research compound for scientific use in a laboratory setting.

Distinction from other GLP-1 agonists

Unlike semaglutide (single GLP-1 agonist) or tirzepatide (dual GLP-1/GIP agonist), retatrutide targets three receptor pathways simultaneously. This triple mechanism distinguishes it in preclinical and clinical research models.

*Nova Labs does not sell medicines and does not provide medical or therapeutic advice. All information is for scientific purposes only.*